The following are some of the biotech stocks that made their way onto the Day’s Gainers & Losers’ list of March 27, 2017.
1. Cellect Biotechnology Ltd. (APOP)
Gained 74% to close Monday’s (Mar.27) trading at $10.90.
News: The Company’s first stem cell transplant procedure has been successfully performed using its ApoGraft technology in its phase I/II clinical trial in a blood cancer patient.
The independent Data and Safety Monitoring Board (DSMB) has given the go-ahead for enrolling additional 2 cancer patients for ApoGraft transplantation treatments.
ApoGraft aims to become a game changer in stem cells transplantations for cancer treatments.
Up to 50 percent of stem cell transplant procedures, such as bone marrow transplants, results in life-threatening rejection disease, known as Graft-versus-Host-Disease.
2. Impax Laboratories Inc. (IPXL)
Gained 37.30% to close Monday’s trading at $12.70.
News: The Company has hired Morgan Stanley to explore strategic alternatives, including a possible sale, according to Reuters.
Paul Bisaro has been appointed Impax’s President and Chief Executive Officer and a member of the Company’s Board, effective March 27, 2017. Bisaro succeeds Kevin Buchi, who has served as Interim President and Chief Executive Officer since December of 2016.
3. Cancer Genetics Inc. (CGIX)
Gained 29.49% to close Monday’s trading at $5.05.
News: No news
Recent event: On Mar.23rd, the Company reported record revenue for the fourth quarter and full-year 2016.
Fourth quarter revenues were up 32% year-over-year on strong organic growth to $7.2 million while full-year 2016 revenues were up 50% year-over-year to $27 million.
Net loss improved to $2.8 million or $0.15 per share during the fourth quarter of 2016 compared to a net loss of $5.7 million or $0.48 per share during the fourth quarter of 2015.
During 2017, the Company expects its business to continue high double-digit, durable growth.
4. Regulus Therapeutics Inc. (RGLS)
Gained 21.43% to close Monday’s trading…